[1]
Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin., 2018, 68(6), 394-424.
[2]
Collins, F.S.; Varmus, H. A new initiative on precision medicine. Eng. J. Med, 2015, 372(9), 793-795.
[3]
Yong-Tao, D.; Chetan, B.S.; Wei, L.; Kunjal, V.S.; Yongfang, Y. New promises to cure cancer and other genetic diseases/disorders: Epi-drugs through epigenetics. Curr. Top. Med. Chem., 2019, 19, 1-23.
[4]
Yongtao, D.; Wei, L.; Liang, T.; Yanna, M.; Chuanjun, S. Targeting tubulin-colchicine site for cancer therapy: Inhibitors, antibody- drug conjugates and degradation agents. Curr. Top. Med. Chem., 2019, 19, 1-16.
[5]
Aronson, S.J.; Rehm, H.L. Building the foundation for genomics in precision medicine. Nature, 2015, 526, 336.
[6]
Deng, X.; Nakamura, Y. Cancer precision medicine: from cancer screening to drug selection and personalized immunotherapy. Trends Pharmacol. Sci., 2017, 38(1), 15-24.
[7]
Wu, T.; Dai, Y. Tumor microenvironment and therapeutic response. Cancer Lett., 2017, 387, 61-68.
[8]
Turley, S.J.; Cremasco, V.; Astarita, J.L. Immunological hallmarks of stromal cells in the tumour microenvironment. Nat. Rev. Immunol., 2015, 15, 669-682.